Synopsis
The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers.
In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost.
"synopsis" may belong to another edition of this title.
About the Author
DR. CHARLES THEUER has been CEO and President and a Director of TRACON Pharmaceuticals since 2006. Dr. Theuer has been instrumental in bringing novel blockbuster oncology drugs to market, including Sutent® to treat advanced kidney cancer, while working as Director of Clinical Oncology at Pfizer. Dr. Theuer has held senior management positions at notable biotechnology firms, including TargeGen, Inc., and IDEC Pharmaceutical Corp. He has worked at the National Cancer Institute and held academic positions at the University of California, Irvine. He completed a general surgery residency program at Harbor-UCLA Medical Center and was board certified in general surgery in 1997. Dr. Theuer’s previous research involved immunotoxin and cancer vaccine development, translational work in cancer patients, and gastrointestinal cancer epidemiology. He is married with two adult children and enjoys hiking, coaching basketball, and sculling.
"About this title" may belong to another edition of this title.
Search results for Unnecessary Expense: An Antidote for the Billion Dollar...
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: World of Books (was SecondSale), Montgomery, IL, U.S.A.
Seller rating 5 out of 5 stars
Condition: Very Good. Item in very good condition! Textbooks may not include supplemental items i.e. CDs, access codes etc. Seller Inventory # 00089253441
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: Bookmonger.Ltd, HILLSIDE, NJ, U.S.A.
Seller rating 4 out of 5 stars
hardcover. Condition: Very Good. Crease on cover*. Seller Inventory # mon0000707194
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem Format: Hardcover
Seller: INDOO, Avenel, NJ, U.S.A.
Seller rating 5 out of 5 stars
Condition: As New. Unread copy in mint condition. Seller Inventory # PG9781950863570
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem Format: Hardcover
Seller: INDOO, Avenel, NJ, U.S.A.
Seller rating 5 out of 5 stars
Condition: New. Brand New. Seller Inventory # 9781950863570
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: Lakeside Books, Benton Harbor, MI, U.S.A.
Seller rating 5 out of 5 stars
Condition: New. Brand New! Not Overstocks or Low Quality Book Club Editions! Direct From the Publisher! We're not a giant, faceless warehouse organization! We're a small town bookstore that loves books and loves it's customers! Buy from Lakeside Books! Seller Inventory # OTF-S-9781950863570
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: California Books, Miami, FL, U.S.A.
Seller rating 5 out of 5 stars
Condition: New. Seller Inventory # I-9781950863570
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: Lucky's Textbooks, Dallas, TX, U.S.A.
Seller rating 5 out of 5 stars
Condition: New. Seller Inventory # ABLIING23Mar3012140058857
Stock Image
Unnecessary Expense (Hardcover)
Seller: Grand Eagle Retail, Bensenville, IL, U.S.A.
Seller rating 5 out of 5 stars
Hardcover. Condition: new. Hardcover. The drug development process in the United States has become so weighted down by a business-as-usual paradigm that an average of more than $2 billion is spent to secure FDA approval for every new drug. Because the investment required is so extreme, drug development companies are understandably focused on discovering and developing drugs designed for large patient populations: diseases experienced by millions, such as high blood pressure, diabetes, or some of the more common cancers. In Unnecessary Expense, Dr. Charles Theuer, CEO of TRACON Pharmaceuticals, outlines the problem and offers a solution: an aligned and streamlined model that emphasizes quality and reduces the time and cost of drug development, while also harnessing global innovation to benefit patients with rare diseases in urgent need of new treatments. Here Dr. Theuer shows the value of a pharmaceutical paradigm shift, to enable the development of drugs for patients who need them, at a fraction of the time and cost. Shipping may be from multiple locations in the US or from the UK, depending on stock availability. Seller Inventory # 9781950863570
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: Russell Books, Victoria, BC, Canada
Seller rating 4 out of 5 stars
hardcover. Condition: New. Special order direct from the distributor. Seller Inventory # ING9781950863570
Buy New
US$ 29.99
US$ 19.99 shipping
Ships from Canada to U.S.A.
Ships from Canada to U.S.A.
Quantity: 17 available
Stock Image
Unnecessary Expense: An Antidote for the Billion Dollar Drug Problem
Seller: Chiron Media, Wallingford, United Kingdom
Seller rating 4 out of 5 stars
Hardcover. Condition: New. Seller Inventory # 6666-ING-9781950863570
Buy New
US$ 29.98
US$ 20.79 shipping
Ships from United Kingdom to U.S.A.
Ships from United Kingdom to U.S.A.
Quantity: 17 available